Autres langues Prostatype Genomics AB

Actions

PROGEN

SE0014684569

Temps Différé Nasdaq Stockholm Autres places de cotation 10:36:17 03/05/2024			Varia. 5j.	Varia. 1 janv.
0,036 ^SEK	-2,17 %		-11,76 %	-62,11 %

18/04	Prostatype Genomics annonce de très bons résultats provisoires de l'étude de suivi à long terme avec Prostatype à Uppsala	CI
17/04	Prostatype Genomics fait le point sur les progrès importants de l'étude américaine sur Prostatype®.	CI

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Prostatype Genomics publishes Annual Report for 2023	25/04
NOTICE OF ANNUAL GENERAL MEETING IN PROSTATYPE GENOMICS AB (PUBL)	24/04
Prostatype Genomics announces outcome of exercise of warrants of series 3 (TO3)	19/04
Prostatype Genomics announces very strong interim results from long-term follow-up study with Prostatype® in Uppsala	18/04
Prostatype Genomics Announces Very Strong Interim Results from Long-Term Follow-Up Study with Prostatype in Uppsala	18/04
Prostatype Genomics updates on significant progress in the US study with Prostatype®	17/04
Prostatype Genomics Updates on Significant Progress in the US Study with Prostatype®	17/04
Prostatype Genomics Wraps Up Prostate Cancer Genetic Test Study with Positive Results	16/04
Prostatype Genomics announces strong positive final results from multicentre study with Prostatype® in Spain	16/04
Prostatype Genomics Announces Strong Positive Final Results from Multicentre Study with Prostatype®? in Spain	16/04
Prostatype Genomics AB Announces Strong Positive Final Results from Multicentre Study with Prostatype in Spain	16/04
The exercise period for Prostatype Genomic's warrants of series 3 begins today	05/04
Prostatype Genomics enters into collaboration with Professor E. David Crawford, MD, University of California San Diego, in preparation for the commercial launch of Prostatype® in the United States	02/04
Prostatype Genomics Enters into Collaboration with Professor E. David Crawford University of California San Diego, in Preparation for the Commercial Launch of Prostatype in the United States	02/04
Prostatype Genomics publishes newsletter on US progress and the long-term follow-up study in Uppsala	11/03
Prostatype Genomics' long-term study with Uppsala University Hospital will be presented at the AUA conference in the US in May 2024	19/02
Prostatype Genomics AB Reports Earnings Results for the Full Year Ended December 31, 2023	15/02
Prostatype Genomics publishes year-end report for 2023	15/02
Prostatype Genomics receives CAP laboratory accreditation, achieves another milestone towards entering the US market	09/02
Prostatype Genomics acquires CLIA Certificate to facilitate rapid US market launch with a significantly stronger financial outlook	08/02

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Prostatype Genomics AB

Actions

PROGEN

SE0014684569

Autres langues

Filtres